The Association of the British Pharmaceuticals Industry (ABPI) has responded to the International Comparisons of Health Technology Assessment report, published today, and also addressed claims that patients are being denied life-prolonging treatments for cancer.
14 Aug 2016 Posted in News Release By Paul Catchpole
Notes to editors
For more information and background read, 'Will the new CDF provide a better deal for cancer patients?' by Dr Paul Catchpole, published on Monday 11 July.
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90 per cent of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.